Mexico José Luis Hernández, general manager at Kedrion Mexico, explains the strategy followed by the affiliate in Mexico to obtain success during the past eight years and showcases the added value of plasma-derivate solutions both for patients and government. What are the primary activities and operations of Kedrion in Mexico? Kedrion…
Switzerland With a population of only 350,000, Ticino has a remarkably well developed pharmaceutical cluster. FIT Chairman Giorgio Calderari explains that the cluster’s key strength lies in the diverse range of capabilities which its members are able to offer as contract services to one another, and of course other interested third…
Taiwan Terry Lin, general manager, and Freia Wei, director for international business at UniPharma, on the company’s move from specialty distribution to drug development and diagnostic products. With an upcoming IPO, UniPharma is considering both organic and inorganic development opportunities to further nurture its geographical expansion. Being one of the best-established…
Mexico Maarten Pouw, business unit director of Mexico and Latin America at DSM Sinochem Pharmaceuticals, explains the crucial role that sustainable antibiotics play in combating antimicrobial resistance and showcases the company’s region-wide commitment to offering reliable, compliant and sustainable APIs. Could you please introduce to our international audience the key activities…
USA While pledging to lower drug prices has proved popular, the Trump administration’s proposed FDA reform has been getting some pharmaceutical executives worried. In a meeting with Big Pharma CEOs at the end of January; US President Donald Trump called for drug prices to be lowered, US production of medicines to…
Taiwan Yita Lee & Muh-Hwan Su of Sinphar Group & SynCore Bio describe the exciting R&D projects of SynCore Bio, the oncology & dry AMD focused innovation-driven company of the group, and the advantages of SynCore Bio’s integration within Sinphar Group. As an introduction to our international readers, could you provide…
Ireland Grünenthal Ireland’s General Manager discusses the incredible growth of the Irish affiliate over the past twelve years, their comprehensive pain portfolio, the innovation they are bringing as pain specialists to the industry, and his strategy for increasing revenues in the next five years. You were the founder of Grünenthal’s Irish…
Switzerland Niche generics manufacturer Rivopharm was nearly bankrupt when acquired by current president and CEO Piero Poli in 2005; he explains the changes and strategy he put in place to drive the company to over 5x growth in the last 12 years while successfully bringing the first generics of several niche…
Ireland Much like the Irish sport of hurling, conducting R&D in Ireland is something often overlooked – unfairly, as proponents would say. Ireland has always faced a number of intrinsic hurdles in this space, not least the small patient population and more recently, the economic crisis, which forced the Irish healthcare…
Ireland Sorcha McKenna, Partner at McKinsey & Company in Ireland, discusses the current trends in the Irish healthcare and life sciences sector, the potential behind both tech and integrated care for the industry, as well as some of the biggest evolutions she has seen during her 14-year career with the company.…
Pharma Do phenomenons such as Brexit and the Trump election victory mean trouble for the pharma industry or are you more optimistic? Take the PharmaBoardroom poll on the pharma industry in 2017 and stay tuned for the results! Create your own user feedback survey
Mexico GM Gerardo Torres-Septién explains how Grupo Rasch has managed to grow during the last two years and showcases the added value of its solutions to help the pharmaceutical industry enhance its cost structure and efficiency ratios. Could you please give an update to our international audience about the operations and…
See our Cookie Privacy Policy Here